NIKE (NKE) Q1 FY2027 Earnings Call: Guidance and Outlook
Formal guidance was provided for the full fiscal year 2027, outlining expectations for revenue declines, profitability, and adjusted earnings per share.
About NIKE. , through its various subsidiaries, operates as a global enterprise focused on the design, development, marketing, and sale of athletic footwear, apparel, equipment, and accessories for all ages and genders.
Call date
Sentiment score
-5 Cautious
Management tone, -100 to +100
Sentiment change
-15
vs Q4 FY2026 call
Sector
Consumer Discretionary, Textiles, Apparel and Luxury Goods
Revenues are expected to decline in the high single-digit range for fiscal 2027.
EBIT
EBIT is expected to decline by a greater percentage than revenue.
Adjusted EPS
Adjusted earnings per share are expected to be in the range of $1.15 to $1.35, excluding approximately $0.15 of impact from the Pace program.
Outlook
Marketplace cleanup
Management expects deliberate actions to reduce supply across key parts of the marketplace to support full-price realization, creating revenue pressure for the remainder of fiscal 2027 and into 2028.
Greater China trajectory
Revenue performance in Greater China is expected to get worse for the balance of the year as the digital cleanup and inventory reset take multiple seasons.
SG&A expenses
SG&A is expected to remain down year-over-year as operations are simplified and productivity is increased across the organization.
Pace program savings
The Pace program is expected to deliver approximately $2.5 billion in savings, with the majority realized in fiscal years 2029 and 2030, and full realization continuing into fiscal 2031.
Dombey's summary of the NIKE Q1 FY2027 earnings call held Oct 1, 2026, written from the call itself. Every figure on this page was checked against what was said on the call, and quoted lines are management's own words; we do not add estimates or prices. The tone score is our read of management's wording, guidance and answers. Check figures against the company's SEC filings before acting. This is research, not investment advice.
